Spartan Fund Management’s DA32 Life Science Tech Acquisition Corp. Class A Common Stock DALS Stock Holding History

Spartan Fund Management’s Portfolio DALS Stock Details DALS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-282,680	Closed	-$4.05M	–	369
2023 Q2	$4.05M	Buy	282,680 +266,537	+1,651%	+$2.72M	0.98%	39
2023 Q1	$163K	Buy	16,143 +1,319	+9%	+$13.3K	0.08%	158
2022 Q4	$147K	Hold	14,824	–	–	0.05%	205
2022 Q3	$144K	Hold	14,824	–	–	0.04%	268
2022 Q2	$144K	Hold	14,824	–	–	0.03%	324
2022 Q1	$181K	Buy	+14,824	New	+$143K	0.03%	316

Spartan Fund Management's DALS Position: Q3 2023 in Review

Spartan Fund Management sold out of DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) in Q3 2023, closing a stake of 282,680 shares — an estimated $4.05M sold.

Spartan Fund Management first reported a position in DALS in Q1 2022 and held it in 6 quarters. The position peaked at $4.05M in Q2 2023. 0 funds tracked by Wall St. Rank hold DALS as of Q3 2023.

Spartan Fund Management reported no remaining DA32 Life Science Tech Acquisition Corp. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Spartan Fund Management sold 282,680 DA32 Life Science Tech Acquisition Corp. Class A Common Stock shares in Q3 2023, an estimated $4.05M.
Spartan Fund Management first reported a position in DA32 Life Science Tech Acquisition Corp. Class A Common Stock in Q1 2022 and held it in 6 quarters.
Spartan Fund Management's DA32 Life Science Tech Acquisition Corp. Class A Common Stock position peaked at $4.05M in Q2 2023.
0 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp. Class A Common Stock as of Q3 2023.

Based on Spartan Fund Management's 13F filing for Q3 2023, filed 23 Oct 2023.